Author:
Levin Myron J.,Ustianowski Andrew,De Wit Stephane,Beavon Rohini,Thissen Jesse,Seegobin Seth,Dey Kanika,Near Karen A.,Streicher Katie,Kiazand Alexandre,Esser Mark T.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Trans Med 2022;14(635):eabl8124.
2. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–9.
3. Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188–200.
4. Levin MJ, Ustianowski A, Thomas S, et al. AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin Infect Dis. 2023;76(7):1247–56.
5. United States Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld™ (tixagevimab co-packaged with cilgavimab). 2023. https://www.fda.gov/media/154701/download. Accessed Feb 19 2024.